„“Drug counterfeiting is a serious and growing problem and RFID offers the potential to be an important anti-counterfeiting technology in the future. It’s certainly not the only solution. Changes to state regulations, more stringent licensing of pharmaceutical wholesalers, modifications of business practices, and increased enforcement also are very important. But RFID does offer great promise as an effective tool in the battle against counterfeiting,““ erklärt Tom McPhillips, Vizepräsident des Unternehmens. Neben Pfizer planen auch andere Pharmahersteller wie GlaxoSmithKline und Purdue Pharma für das nächste Jahr die Einführung von RFID. www.pfizer.com